Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 613-622 , August 2009

Synthesis, radiolabeling, in vitro and in vivo evaluation of [18F]-FPECMO as a positron emission tomography radioligand for imaging the metabotropic glutamate receptor subtype 5

Received 12 December 2008 ,Revised 5 March 2009 ,Accepted 16 March 2009.

References 

  1. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7–61
  2. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995;34:1–26
  3. Abe T, Sugihara H, Nawa H, Shigemoto R, Mizuno N, Nakanishi S. Molecular characterization of a novel metabotropic glutamate receptor mGluR5coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem. 1992;267:13361–13368
  4. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett. 1993;163:53–57
  5. Palucha A, Branski P, Szewczyk B, Wieronska JM, Klak K, Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav. 2005;81:901–906
  6. Allgeier H, Cosford ND, Flor PJ, et al. mGluR5 antagonists for the treatment of pain and anxiety. European Patent. 2003;[EP01 117 403]
  7. Spooren W, Gasparini F. mGlu5 receptor antagonists: a novel class of anxiolytics. Drug News Perspect. 2004;17:251–257
  8. Tatarczynska E, Klodzinska A, Chojnacka-Wójcik E, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132:1423–1430
  9. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther. 2000;88:427–435
  10. Marino MJ, Conn JP. Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. Curr Drug Targets CNS Neurol Disord. 2002;1:239–250
  11. Ametamey SM, Kessler LJ, Honer M, et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med. 2006;47:698–705
  12. Ametamey SM, Treyer V, Streffer J, et al. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med. 2007;48:247–252
  13. Hamill TG, Krause S, Ryan C, et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5. Synapse. 2005;56:205–216
  14. Patel S, Hamill TG, Connolly B, Jagoda E, Li Gibson RE. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nuc Med Biol. 2007;34:1009–1017
  15. Wang JQ, Tueckmantel W, Zhu A, Pellegrino D, Brownwell AL. Synthesis and preliminary biological evaluation of 3-[18F]fuoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse. 2007;61:951–961
  16. Siméon FG, Brown AK, Zoghbi SS, Patterson VM, Innis RB, Pike VW. Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. J Med Chem. 2007;50:3256–3266
  17. Brown AK, Kimura Y, Zoghbi SS, Siméon FG, Liow JS, Kreisl WC, et al. Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med. 2008;49:2042–2048
  18. Honer M, Stoffel A, Kessler LJ, Schubiger PA, Ametamey SM. Radiolabeling and in vitro and in vivo evaluation of [18F]-FE-DABP688 as a PET radioligand for the metabotropic glutamate receptor subtype 5. Nuc Med Biol. 2007;34:973–980
  19. Strijckmans V, Hunter DH, Dolle F, Coulon C, Loc'h C, Mazière B. Synthesis of a potential M1 muscarinic agent [76Br]bromocaramiphen. J Labelled Compd Radiopharm. 1996;38:471–481
  20. Honer M, Bruhlmeier M, Missimer J, Schubiger AP, Ametamey SM. Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. J Nucl Med. 2004;45:464–470
  21. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond). 1998;23:207–214
  22. Larsen DS, O'Shea MD. Synthetic approaches to the angucycline antibiotics: the total syntheses to (±)-rubiginone B1 and B2, (±)-emycin A, and related analogs. J Chem Soc Perkin Trans 1. 1995;8:1019–1028
  23. Zaidlewicz M, Uzarewicz IG. Reduction of O-methyl oxime ethers of conjugated cyclohexenones with aluminium hydride. Heteroat Chem. 1993;4:73–77
  24. Sonogashira K, Tohda Y, Hagihara NA. Convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes, and bromopyridines. Tetrahedron Lett. 1975;50:4467–4470
  25. Gasparini F, Andres H, Flor PJ, et al. [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett. 2002;12:407–409
  26. Dollé F. [18F]Fluoropyridines: from conventional radiotracers to the labelling of macromolecules such as proteins and oligonucleotides. In: PET Chemistry: the driving force in molecular imaging, Ernst Schering Research Foundation. Berlin: Springer; 2007;p. 113–157
  27. Wilson AA, Houle S. Radiosynthesis of carbon-11 labeled N-methyl-2-(arylthio)benzylamines: potential racers for the serotonin reuptake receptor. J Labelled Compd Radiopharm. 1999;42:1277–1288

PII: S0969-8051(09)00083-3

doi: 10.1016/j.nucmedbio.2009.03.005

Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 613-622 , August 2009

Article Tools

* Image Usage & Resolution